Equities Analysts Set Expectations for Biogen Q2 Earnings

Biogen Inc. (NASDAQ:BIIB) – Equities research analysts at Zacks Research cut their Q2 2025 earnings estimates for Biogen in a note issued to investors on Thursday, May 15th. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will post earnings per share of $4.09 for the quarter, down from their previous forecast of $4.19. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share. Zacks Research also issued estimates for Biogen’s Q3 2025 earnings at $3.85 EPS, Q4 2025 earnings at $3.67 EPS, FY2025 earnings at $14.64 EPS, Q1 2026 earnings at $3.42 EPS, Q3 2026 earnings at $3.74 EPS and Q4 2026 earnings at $3.68 EPS.

Several other research firms have also commented on BIIB. Oppenheimer set a $205.00 price objective on shares of Biogen in a research note on Friday, May 2nd. Citigroup cut their price target on shares of Biogen from $160.00 to $145.00 and set a “neutral” rating on the stock in a report on Thursday, February 13th. Argus lowered shares of Biogen from a “buy” rating to a “hold” rating in a research report on Friday, April 4th. BMO Capital Markets lowered their target price on shares of Biogen from $156.00 to $139.00 and set a “market perform” rating for the company in a research note on Thursday, February 13th. Finally, Robert W. Baird decreased their price objective on shares of Biogen from $300.00 to $255.00 and set an “outperform” rating for the company in a report on Friday, May 2nd. Twenty research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $191.30.

Biogen Stock Performance

NASDAQ BIIB opened at $130.55 on Monday. The business’s 50 day moving average price is $125.55 and its 200-day moving average price is $141.70. Biogen has a fifty-two week low of $110.04 and a fifty-two week high of $238.00. The company has a market cap of $19.13 billion, a P/E ratio of 11.67, a P/E/G ratio of 1.51 and a beta of 0.12. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.90 and a current ratio of 1.35.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Thursday, May 1st. The biotechnology company reported $3.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.26 by ($0.24). The company had revenue of $2.43 billion for the quarter, compared to analysts’ expectations of $2.25 billion. Biogen had a net margin of 16.87% and a return on equity of 14.98%. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter last year, the company earned $3.67 earnings per share.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Focus Partners Wealth increased its holdings in shares of Biogen by 172.2% in the first quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock valued at $1,392,000 after purchasing an additional 6,436 shares during the period. Woodline Partners LP lifted its holdings in Biogen by 42.0% during the first quarter. Woodline Partners LP now owns 125,162 shares of the biotechnology company’s stock valued at $17,127,000 after purchasing an additional 37,005 shares in the last quarter. Empowered Funds LLC grew its position in shares of Biogen by 64.9% in the first quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock valued at $965,000 after purchasing an additional 2,777 shares during the period. MBB Public Markets I LLC purchased a new stake in shares of Biogen during the first quarter worth about $294,000. Finally, United Services Automobile Association acquired a new position in shares of Biogen during the 1st quarter worth about $499,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Insider Transactions at Biogen

In related news, Director Stephen A. Sherwin sold 8,760 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $150.02, for a total value of $1,314,175.20. Following the completion of the transaction, the director now directly owns 11,318 shares of the company’s stock, valued at $1,697,926.36. This trade represents a 43.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.16% of the company’s stock.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.